Cargando…

Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications

A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactiviti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiriyachaiporn, Natpapas, Sirikaew, Siriwan, Chitchai, Nawakarn, Janchompoo, Pareena, Maneeprakorn, Weerakanya, Bamrungsap, Suwussa, Pasomsub, Ekawat, Japrung, Deanpen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033468/
https://www.ncbi.nlm.nih.gov/pubmed/35480952
http://dx.doi.org/10.1039/d1ra01361k
_version_ 1784692895975997440
author Wiriyachaiporn, Natpapas
Sirikaew, Siriwan
Chitchai, Nawakarn
Janchompoo, Pareena
Maneeprakorn, Weerakanya
Bamrungsap, Suwussa
Pasomsub, Ekawat
Japrung, Deanpen
author_facet Wiriyachaiporn, Natpapas
Sirikaew, Siriwan
Chitchai, Nawakarn
Janchompoo, Pareena
Maneeprakorn, Weerakanya
Bamrungsap, Suwussa
Pasomsub, Ekawat
Japrung, Deanpen
author_sort Wiriyachaiporn, Natpapas
collection PubMed
description A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactivities and were used as targeting ligands. With the best antibody pairs selected, the system exhibited good specificity to both viruses without cross reactivity to other closely related respiratory viruses. Further semi-quantitative analysis using a strip reader revealed that the system is capable of detecting influenza A and B protein content as low as 0.04 and 1 ng per test, respectively, using a sample volume as low as 100 μL, within 10 minutes (R(2) = 0.9652 and 0.9718). With a performance comparison to the commercial tests, the system demonstrated a four-to-eight-fold higher sensitivity. Pre-clinical evaluation with 101 nasopharyngeal swabs reveals correlated results with a standard molecular approach, with 89% and 83% sensitivity towards influenza A and B viruses, and 100% specificity for both viruses.
format Online
Article
Text
id pubmed-9033468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90334682022-04-26 Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications Wiriyachaiporn, Natpapas Sirikaew, Siriwan Chitchai, Nawakarn Janchompoo, Pareena Maneeprakorn, Weerakanya Bamrungsap, Suwussa Pasomsub, Ekawat Japrung, Deanpen RSC Adv Chemistry A visual colorimetric rapid screening system based on a lateral flow device for simultaneous detection and differentiation between influenza A and B nucleoprotein as a model was developed. Monoclonal antibodies, specific for either influenza A or B nucleoproteins, were evaluated for their reactivities and were used as targeting ligands. With the best antibody pairs selected, the system exhibited good specificity to both viruses without cross reactivity to other closely related respiratory viruses. Further semi-quantitative analysis using a strip reader revealed that the system is capable of detecting influenza A and B protein content as low as 0.04 and 1 ng per test, respectively, using a sample volume as low as 100 μL, within 10 minutes (R(2) = 0.9652 and 0.9718). With a performance comparison to the commercial tests, the system demonstrated a four-to-eight-fold higher sensitivity. Pre-clinical evaluation with 101 nasopharyngeal swabs reveals correlated results with a standard molecular approach, with 89% and 83% sensitivity towards influenza A and B viruses, and 100% specificity for both viruses. The Royal Society of Chemistry 2021-05-24 /pmc/articles/PMC9033468/ /pubmed/35480952 http://dx.doi.org/10.1039/d1ra01361k Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Wiriyachaiporn, Natpapas
Sirikaew, Siriwan
Chitchai, Nawakarn
Janchompoo, Pareena
Maneeprakorn, Weerakanya
Bamrungsap, Suwussa
Pasomsub, Ekawat
Japrung, Deanpen
Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title_full Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title_fullStr Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title_full_unstemmed Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title_short Pre-clinically evaluated visual lateral flow platform using influenza A and B nucleoprotein as a model and its potential applications
title_sort pre-clinically evaluated visual lateral flow platform using influenza a and b nucleoprotein as a model and its potential applications
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033468/
https://www.ncbi.nlm.nih.gov/pubmed/35480952
http://dx.doi.org/10.1039/d1ra01361k
work_keys_str_mv AT wiriyachaipornnatpapas preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT sirikaewsiriwan preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT chitchainawakarn preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT janchompoopareena preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT maneeprakornweerakanya preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT bamrungsapsuwussa preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT pasomsubekawat preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications
AT japrungdeanpen preclinicallyevaluatedvisuallateralflowplatformusinginfluenzaaandbnucleoproteinasamodelanditspotentialapplications